Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents with bipolar disorders

Mina Hah, Kiki Chang

Research output: Contribution to journalArticle

31 Scopus citations

Abstract

Children and adolescents with bipolar disorder (BD) have a high incidence of comorbid attention-deficit/hyperactivity disorder (ADHD). In this paper, we report a consecutive case series on 7 patients with pediatric BD and ADHD who were treated with atomoxetine-and all but one were also treated in conjunction with mood stabilizers. All patients were outpatients at the Stanford Pediatric Bipolar Disorders Clinic. Information on patients was collected in a retrospective chart review. All but 1 patient demonstrated significant improvement in symptoms of ADHD. No patients had episodes of hypomania or mania during the treatment period. Adverse effects of atomoxetine treatment included sedation, nausea, and decreased appetite. These cases suggest that atomoxetine may be a safe and effective treatment for ADHD in conjunction with mood stabilizers in children with BD.

Original languageEnglish (US)
Pages (from-to)996-1004
Number of pages9
JournalJournal of Child and Adolescent Psychopharmacology
Volume15
Issue number6
DOIs
StatePublished - Dec 2005
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pediatrics, Perinatology, and Child Health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents with bipolar disorders'. Together they form a unique fingerprint.

  • Cite this